文献速递乳腺癌

基于超声的深度学习影像组学评估局部晚期乳腺癌新辅助化疗后病理完全缓解

Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
PubMed 文献 · Eur J Cancer · 2021-02-24

该研究基于治疗前后超声图像提取深度学习与手工影像组学特征,构建并外部验证深度学习影像组学列线图(DLRN),用于术前预测局部晚期乳腺癌新辅助化疗(NAC)后的病理完全缓解(pCR)。外部验证队列中DLRN预测pCR的AUC为0.94(95%CI 0.91-0.97),校准良好,优于临床模型、单一影像组学特征及两位专家的预测,并在激素受体阳性/HER2阴性、HER2阳性和三阴性亚组中均表现良好。

要点

  • DLRN在外部验证队列预测pCR的AUC达0.94,校准良好。
  • DLRN优于临床模型与单一影像组学特征(P<0.05)。
  • 激素受体阳性/HER2阴性、HER2阳性、三阴性亚组AUC分别为0.90、0.95、0.93。

核心结论

  • 基于超声的深度学习影像组学列线图对局部晚期乳腺癌新辅助化疗后pCR具有良好预测价值,可为个体化治疗提供信息。

研究设计与样本

  • 多中心研究,纳入经活检证实的局部晚期乳腺癌并接受术前新辅助化疗的患者。
  • 训练队列来自医院#1,共356例;独立外部验证队列来自医院#2,共236例。
  • 提取治疗前(RS1)与治疗后(RS2)肿瘤表型的深度学习及手工影像组学特征。
  • 采用最小冗余最大相关算法与LASSO回归进行特征选择并构建影像组学特征。
  • 基于影像组学特征与独立临床病理危险因素构建DLRN,并从校准、区分度和临床实用性评估模型。

主要发现

  • DLRN在验证队列预测pCR的受试者工作特征曲线下面积(AUC)为0.94(95%CI 0.91-0.97),校准良好。
  • 在两个队列中DLRN均优于临床模型和单一影像组学特征(P<0.05,DeLong检验)。
  • DLRN预测pCR优于两位专家的预测(总准确率比较均P<0.01)。
  • 外部验证队列中激素受体阳性/HER2阴性、HER2阳性和三阴性亚组的AUC分别为0.90、0.95和0.93。
  • 决策曲线分析证实模型具有临床实用性。

临床怎么用

  • 可作为局部晚期乳腺癌新辅助化疗前评估pCR的辅助工具,帮助筛选适合个体化治疗的患者。
  • 模型基于治疗前后超声图像,需在具备相应影像与算法条件的机构中验证后使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of the study was to develop and validate a deep learning radiomic nomogram (DLRN) for preoperatively assessing breast cancer pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) based on the pre- and post-treatment ultrasound. METHODS: Patients with locally advanced breast cancer (LABC) proved by biopsy who proceeded to undergo preoperative NAC were enrolled from hospital #1 (training cohort, 356 cases) and hospital #2 (independent external validation cohort, 236 cases). Deep learning and handcrafted radiomic features reflecting the phenotypes of the pre-treatment (radiomic signature [RS] 1) and post-treatment tumour (RS2) were extracted. The minimum redundancy maximum relevance algorithm and the least absolute shrinkage and selection operator regression were used for feature selection and RS construction. A DLRN was then developed based on the RSs and independent clinicopathological risk factors. The performance of the model was assessed with regard to calibration, discrimination and clinical usefulness. RESULTS: The DLRN predicted the pCR status with accuracy, yielded an area under the receiver operator characteristic curve of 0.94 (95% confidence interval, 0.91-0.97) in the validation cohort, with good calibration. The DLRN outperformed the clinical model and single RS within both cohorts (P < 0.05, as per the DeLong test) and performed better than two experts' prediction of pCR (both P < 0.01 for comparison of total accuracy). Besides, prediction within the hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2+ and triple-negative subgroups also achieved good discrimination performance, with an AUC of 0.90, 0.95 and 0.93, respectively, in the external validation cohort. Decision curve analysis confirmed that the model was clinically useful. CONCLUSION: A deep learning-based radiomic nomogram had good predictive value for pCR in LABC, which could provide valuable information for individual treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jiang M, Li CL, Luo XM, et al. Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer. 2021. PMID: 33639324. doi:10.1016/j.ejca.2021.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。